Published in Cancer Weekly, October 5th, 2004
The new name more accurately reflects the company's entry into the research, development, and eventual commercialization of plant-derived pharmaceutical and nutraceutical compounds.
"PhytoMedical's entry into biopharmaceutical development is very exciting for all of us, coming on the heels of the company's undertaking to develop a brand-new, plant-derived compound, BDC03," stated Derek J. Cooper, secretary-treasurer of PhytoMedical Technologies.
Named BDC03, the first plant-derived compound to be developed by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-10-05)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.